Navigation Links
Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Date:4/4/2011

ORLANDO, Fla., April 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer.  The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.  

Signaling pathways within cells regulate genes that underlie crucial biological processes including cell division, embryonic development and immunity.  When these networks of proteins misfire, many types of cancer can result.  At AACR, data from Lilly showed how these pipeline molecules target out-of-control signaling pathways.

"Lilly is focused on developing therapies tailored for an individual patient's needs – such as a cancer treatment that targets a specific genetic mutation," said Jonathan M. Yingling, Ph.D., vice president of oncology research at Lilly.  "We believe beginning this evaluation early in the preclinical stage, as we have with these two studies, may lead to more focused, efficient clinical trials and, in turn, speed drug discovery."

LY2784544: JAK2 Inhibitor (Abstract # 2820)

Research presented at AACR's New Small Molecule Therapeutics mini-symposium suggested that the investigational compound LY2784544, a small-molecule JAK2 inhibitor, blocks a specific, difficult-to-isolate, signaling pathway that can lead to the development of cancer cells.  

Specifically, Lilly researchers chose to study inflammatory breast cancer (IBC) cells because these cells support their own survival by secreting chemicals known as growth factors, which allow them to break away from the primary tumor, multiply and then cluster together into tumor sp
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... , December 18, 2014 ... application/module that is used to store, manipulate, and ... comprises a patient tracking and scheduling system, result ... of RIS with HIS and other databases improves ... registration and patient scheduling, patient list management, radiology ...
(Date:12/19/2014)... -- Capnia, Inc. (NASDAQ: CAPN ), ... on its proprietary Sensalyze™ Technology Platform for precision ... for the third quarter and nine months ended ... of our initial public offering (IPO), we are ... CoSense® commercial launch," said Anish Bhatnagar, M.D., Chief ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
... NBIX ) today announced its financial results for ... of 2012, the Company reported net loss of $0.9 million, ... of $2.9 million, or $0.05 income per share, for the ... results is primarily due to the Company,s VMAT2 program moving ...
Cached Medicine Technology:Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
(Date:12/20/2014)... December 21, 2014 BambooIndustry.com is ... Recently, the business has announced its bamboo flooring ... the best material from certified suppliers, and offers ... customers worldwide. In the current promotion, all customers ... off, when they say they know BambooIndustry.com from ...
(Date:12/20/2014)... DePuy Pinnacle hip lawsuits ( ... the artificial hip system was defectively designed continue ... Bernstein Liebhard LLP reports. According to an Order ... on December 2nd, counsel in 10 DePuy Pinnacle ... on November 19, 2014, with depositions to conclude ...
(Date:12/20/2014)... 2014 Angeldress.co.uk, the distinguished wedding dress ... worldwide dress fans. The company has recently updated its ... For the holiday season, Angeldress Blog has ... apparel. , Angeldress.co.uk prides itself in offering a huge ... service. All the company’s outfits are very carefully selected ...
(Date:12/20/2014)... California (PRWEB) December 20, 2014 Developers ... the release of a new plugin for Final Cut ... Studios. , “TranSlice Volume 5 allows users to create ... draw it.” Said Christina Austin, CEO of Pixel Film ... level of professionalism while maintaining an easy to use ...
(Date:12/19/2014)... 2014 Today, Balfleet.com , a ... announces its formal dress promotion. All the old and ... 60% off. , Balfleet.com is well-known for its high ... prom dresses, cocktail dresses and more. Its formal dresses ... guarantee, and they can create an elegant look when ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... found in 18-month study , , WEDNESDAY, Jan. 23 (HealthDay News) ... heart attacks than stents for people with blockages of at ... finding is far from the last word on the stent-versus-surgery ... Hannan, associate dean for research at the State University of ...
... site of blood clot, study reports , , WEDESDAY, Jan. ... directly in the brain may benefit ischemic stroke patients ... drugs. , So says a U.S. study that was ... International Symposium on Endovascular Therapy, in Hollywood, Fla. , ...
... device has pulled adult stem cells out of a living ... The test of the device designed by Michael R. King, ... will be reported in the March 3 issue of the ... that, before we tried it, we never would have expected ...
... MUNDELEIN, Ill., Jan. 23 Z Trim Holdings,Inc. (Amex: ... headline-making,salad dressings., The retail debut of the dressing line ... Z Trim Creamy Italian via both the company,s web site,and ... "We believe the time is right to transfer some ...
... Bipartisan Legislation, The Breast, Cancer Patient Protection Act, ... and Representatives DeLauro (D-CT) and Moran (R-KS) -, - ... Campaign to Encourage Women to Speak Out on ... Today, at a Capitol Hill,press conference, actress Marcia Cross joined ...
... brain region that controls the decision to halt your ... that leftover chicken leg. Whats more, they said, such ... addiction and mental illness., Emmanuel Procyk and colleagues published ... the journal Neuron, published by Cell Press. , In ...
Cached Medicine News:Health News:Surgery Better Than Stents for Multiple Blockages 2Health News:Surgery Better Than Stents for Multiple Blockages 3Health News:Advanced Therapy Aids Stroke Patients 2Health News:Advanced Therapy Aids Stroke Patients 3Health News:Engineers use blood's hydrodynamics to manipulate stem, cancer cells 2Health News:Engineers use blood's hydrodynamics to manipulate stem, cancer cells 3Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 4Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 5Health News:Researchers identify brain's 'eureka' circuitry 2
New!...
...
Mendez Multi-Purpose LASIK Forceps. To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps, Titanium...
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
Medicine Products: